CHO - System Licensing
CHO Edge uses a transposase-based system. We have observed the CHO Edge transposase-mediated integration drives >80% titer stability over 75 generations.
This is some text inside of a div block. Great
Related FAQs
How many copies of the antibody-expressing plasmid end up in the cell line when using a transposase?
This is some text inside of a div block.
White Paper
Video
White Paper - Quantitative Synthetic Biology for Biologics Production
This is some text inside of a div block.
Video
White Paper
Improving Gene Therapy Design and Manufacturability Using Synthetic Biology and AI
This is some text inside of a div block.
Video
White Paper
Model-driven synbio approaches to engineer improved stable cell lines for lentivirus manufacturing
This is some text inside of a div block.
Video
White Paper
Reducing Cost and Risk in Lentiviral Manufacturing with the LV Edge Packaging System
This is some text inside of a div block.
Video
White Paper
Advanced process development to tune product quality (Cell UK 2023)
This is some text inside of a div block.
Video
White Paper
Quantitative Synthetic Biology to Advance Biologics Production (Bioprocessing Summit 2023)
This is some text inside of a div block.